Carboplatin-Induced Ototoxicity in Children Treated for Retinoblastoma.

Background: The chemotherapy regimen comprising carboplatin, vincristine, and etoposide (JOE) is commonly used to treat retinoblastoma. Carboplatin-induced ototoxicity is infrequently reported. Extended high-frequency hearing loss may impair cochlear function and speech-in-noise recognition and elevate hearing thresholds.